VASOSTRICT Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Vasostrict patents expire, and what generic alternatives are available?
Vasostrict is a drug marketed by Par Sterile Products and is included in one NDA. There are fourteen patents protecting this drug and four Paragraph IV challenges.
The generic ingredient in VASOSTRICT is vasopressin. There are nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the vasopressin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vasostrict
A generic version of VASOSTRICT was approved as vasopressin by AM REGENT on August 3rd, 2020.
Summary for VASOSTRICT
| US Patents: | 14 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 12 |
| Clinical Trials: | 3 |
| Patent Applications: | 3 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VASOSTRICT |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VASOSTRICT |
| What excipients (inactive ingredients) are in VASOSTRICT? | VASOSTRICT excipients list |
| DailyMed Link: | VASOSTRICT at DailyMed |
Recent Clinical Trials for VASOSTRICT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| La Jolla Pharmaceutical Company | Phase 4 |
| University of New Mexico | Phase 4 |
| National Center for Advancing Translational Science (NCATS) | Phase 4 |
Paragraph IV (Patent) Challenges for VASOSTRICT
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VASOSTRICT | Injection | vasopressin | 20 units/100 mL | 204485 | 1 | 2022-12-20 |
| VASOSTRICT | Injection | vasopressin | 40 units/100 mL and 60 units/100 mL | 204485 | 1 | 2022-02-28 |
| VASOSTRICT | Injection | vasopressin | 200 units/10 mL | 204485 | 1 | 2018-06-29 |
| VASOSTRICT | Injection | vasopressin | 20 units/mL, 1 mL | 204485 | 1 | 2018-03-23 |
US Patents and Regulatory Information for VASOSTRICT
VASOSTRICT is protected by fourteen US patents.
Patents protecting VASOSTRICT
Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Sterile Products | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-002 | Dec 17, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Par Sterile Products | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-004 | Apr 15, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Par Sterile Products | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-002 | Dec 17, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Par Sterile Products | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-004 | Apr 15, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Par Sterile Products | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-001 | Apr 17, 2014 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Par Sterile Products | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-003 | Apr 15, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Par Sterile Products | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-004 | Apr 15, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
